CoChat
Sign Up
Cited by 40

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Recent advances in exosome-based immunotherapy applied to cancer

Xie, Jindong, Zheng, Zihan, Tuo, Ling, Deng, Xinpei, Tang, Hailin, Peng, Cheng, Zou, Yutian·2023·Frontiers in Immunology
DOI 10.3389/fimmu.2023.1296857PMC PMC10662326
Open this paper in CoChat — free account

Abstract

Cancer stands as a prominent contributor to global mortality rates, necessitating immediate attention toward the exploration of its treatment options. Extracellular vesicles have been investigated as a potential cancer therapy in recent years. Among them, exosomes, as cell-derived nanovesicles with functions such as immunogenicity and molecular transfer, offer new possibilities for immunotherapy of cancer. However, multiple studies have shown that exosomes of different cellular origins have different therapeutic effects. The immunomodulatory effects of exosomes include but are not limited to inhibiting or promoting the onset of immune responses, regulating the function of molecular signaling pathways, and serving as carriers of antitumor drugs. Therefore, this mini-review attempts to summarize and evaluate the development of strategies for using exosomes to package exogenous cargos to promote immunotherapy in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1296857

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The immunostimulatory and inhibitory effects of exosomes. This schematic shows the basic structure of exosomes and the mechanisms and functions of exosomes released by a variety of cells in regulating the immune response of tumor-bearing hosts. MHC, major histocompatibility complex; ICAM, intercellular cell adhesion molecule; CTLs, cytotoxic T lymphocytes; Tregs, regulatory cells, TDEs, tumor cell–derived exosomes .
Figure 1 The immunostimulatory and inhibitory effects of exosomes. This schematic shows the basic structure of exosomes and the mechanisms and functions of exosomes released by a variety of cells in regulating the immune response of tumor-bearing hosts. MHC, major histocompatibility complex; ICAM, intercellular cell adhesion molecule; CTLs, cytotoxic T lymphocytes; Tregs, regulatory cells, TDEs, tumor cell–derived exosomes .CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 70

  1. Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity., 11, 10.1016/S1074-7613(00)80089-8 · DOI · Paper page
  2. Aung, 2017, Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action, Int J Mol Sci, 18, 656, 10.3390/ijms18030656 · DOI
  3. Shi, 2017, Cancer nanomedicine: progress, challenges and opportunities, Nat Rev Cancer., 17, 20, 10.1038/nrc.2016.108 · DOI · Paper page
  4. Kennedy, 2020, A review of cancer immunotherapy toxicity, CA Cancer J Clin, 70, 86, 10.3322/caac.21596 · DOI
  5. Igarashi, 2020, Cancer vaccines: toward the next breakthrough in cancer immunotherapy, J Immunol Res, 2020, 5825401, 10.1155/2020/5825401 · DOI
  6. Xu, 2020, Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold, J Cell Commun Signal, 14, 10.1007/s12079-020-00547-6 · DOI
  7. Zhang, 2019, Exosomes in cancer development, metastasis, and immunity, Biochim Biophys Acta Rev Cancer., 1871, 10.1016/j.bbcan.2019.04.004 · DOI · Paper page
  8. Li, 2021, Expression, regulation, and function of exosome-derived miRNAs in cancer progression and therapy, FASEB J, 35, 10.1096/fj.202100294RR · DOI
  9. Syn, 2017, Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges, Trends Biotechnol, 35, 10.1016/j.tibtech.2017.03.004 · DOI
  10. Zhou, 2021, Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment, Biomaterials., 268, 120546, 10.1016/j.biomaterials.2020.120546 · DOI · Paper page
  11. Wang, 2022, Research advances of immunotherapy of exosome PD-L1 in non-small cell lung cancer, Zhongguo Fei Ai Za Zhi., 25, 10.3779/j.issn.1009-3419.2022.102.33 · DOI
  12. Xie, 2022, Exosome-mediated immunosuppression in tumor microenvironments, Cells, 11, 1946, 10.3390/cells11121946 · DOI
  13. Dai, 2020, Exosomes: key players in cancer and potential therapeutic strategy, Signal Transduct Target Ther, 5, 145, 10.1038/s41392-020-00261-0 · DOI · Paper page
  14. Xu, 2020, Exosome-based immunotherapy: a promising approach for cancer treatment, Mol Cancer., 19, 160, 10.1186/s12943-020-01278-3 · DOI · Paper page
  15. Wang, 2020, Dendritic cell biology and its role in tumor immunotherapy, J Hematol Oncol, 13, 107, 10.1186/s13045-020-00939-6 · DOI
  16. Viaud, 2010, Dendritic cell-derived exosomes for cancer immunotherapy: what's next, Cancer Res, 70, 10.1158/0008-5472.CAN-09-3276 · DOI
  17. Yang, 2018, Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth, Cell Res, 28, 10.1038/s41422-018-0060-4 · DOI
  18. Camuzard, 2020, Autophagy in the crosstalk between tumor and microenvironment, Cancer Lett, 490, 10.1016/j.canlet.2020.06.015 · DOI
  19. Yin, 2021, HIF-1alpha downregulation of miR-433-3p in adipocyte-derived exosomes contributes to NPC progression via targeting SCD1, Cancer Sci, 112, 10.1111/cas.14829 · DOI
  20. Wang, 2021, CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion, Cell Death Dis, 12, 1065, 10.1038/s41419-021-04359-3 · DOI
  21. Li, 2021, Exosomes Derived from RM-1 Cells Promote the Recruitment of MDSCs into Tumor Microenvironment by Upregulating CXCR4 via TLR2/NF-kappaB Pathway, J Oncol, 2021, 5584406, 10.1155/2021/5584406 · DOI
  22. Liu, 2022, Exosomal circPVT1 derived from lung cancer promotes the progression of lung cancer by targeting miR-124-3p/EZH2 axis and regulating macrophage polarization, Cell Cycle, 21, 10.1080/15384101.2021.2024997 · DOI
  23. Hon, 2019, Extracellular Vesicle-derived circular RNAs confers chemoresistance in Colorectal cancer, Sci Rep, 9, 16497, 10.1038/s41598-019-53063-y · DOI
  24. Ni, 2020, Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+gammadelta1 Treg cells, Signal Transduct Target Ther, 5, 41, 10.1038/s41392-020-0129-7 · DOI
  25. Ashrafizadeh, 2020, PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs, Life Sci, 256, 117899, 10.1016/j.lfs.2020.117899 · DOI
  26. Ma, 2021, M2 macrophage-derived exosomal microRNA-155-5p promotes the immune escape of colon cancer by downregulating ZC3H12B, Mol Ther Oncolytics., 20, 10.1016/j.omto.2021.02.005 · DOI
  27. de Souza, 2009, Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses, Expert Rev Anticancer Ther, 9, 10.1586/era.09.88 · DOI
  28. Wan, 2020, Tumor-derived exosomes (TDEs): How to avoid the sting in the tail, Med Res Rev, 40, 385, 10.1002/med.21623 · DOI
  29. Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331 · DOI · Paper page
  30. Morrissey, 2020, Exosomal PD-L1: roles in tumor progression and immunotherapy, Trends Cancer., 6, 10.1016/j.trecan.2020.03.002 · DOI
  31. Ye, 2016, Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma, J Pathol, 240, 10.1002/path.4781 · DOI
  32. Li, 2015, Esophageal cancer-derived microvesicles induce regulatory B cells, Cell Biochem Funct, 33, 10.1002/cbf.3115 · DOI
  33. Tesone, 2013, Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer, Front Immunol, 4, 10.3389/fimmu.2013.00435 · DOI
  34. Nguyen, 2010, Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism, Proc Natl Acad Sci U S A., 107, 10.1073/pnas.1014465107 · DOI
  35. Whiteside, 2013, Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes), Biochem Soc Trans, 41, 10.1042/BST20120265 · DOI
  36. Jia, 2017, Exosome: emerging biomarker in breast cancer, Oncotarget., 8, 10.18632/oncotarget.16684 · DOI
  37. Whiteside, 2015, The potential of tumor-derived exosomes for noninvasive cancer monitoring, Expert Rev Mol Diagn., 15, 10.1586/14737159.2015.1071666 · DOI
  38. Wu, 2021, A circulating exosome RNA signature is a potential diagnostic marker for pancreatic cancer, a systematic study, Cancers (Basel), 13, 2565, 10.3390/cancers13112565 · DOI
  39. Wei, 2021, Serum exosomal ephA2 is a prognostic biomarker in patients with pancreatic cancer, Cancer Manag Res, 13, 10.2147/CMAR.S304719 · DOI
  40. Wang, 2022, Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients, Clin Exp Immunol, 208, 10.1093/cei/uxac045 · DOI
  41. Chen, 2018, Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response, Nature., 560, 10.1038/s41586-018-0392-8 · DOI · Paper page
  42. Menck, 2017, Neutral sphingomyelinases control extracellular vesicles budding from the plasma membrane, J Extracell Vesicles., 6, 1378056, 10.1080/20013078.2017.1378056 · DOI
  43. Lindenbergh, 2020, Dendritic cells release exosomes together with phagocytosed pathogen; potential implications for the role of exosomes in antigen presentation, J Extracell Vesicles., 9, 1798606, 10.1080/20013078.2020.1798606 · DOI
  44. Chaput, 2004, Exosome-based immunotherapy, Cancer Immunol Immunother., 53, 10.1007/s00262-003-0472-x · DOI
  45. Wang, 2013, Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice, Breast Cancer Res Treat, 140, 10.1007/s10549-013-2626-7 · DOI
  46. Amigorena, 2000, Cancer immunotherapy using dendritic cell-derived exosomes, Medicina (B Aires)., 60
  47. Carmi, 2015, Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity, Nature., 521, 99, 10.1038/nature14424 · DOI
  48. Carreno, 2015, Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells, Science., 348, 10.1126/science.aaa3828 · DOI · Paper page
  49. Reap, 2018, Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma, Cancer Res, 78, 10.1158/0008-5472.CAN-17-0469 · DOI
  50. Lowenfeld, 2017, Dendritic cell vaccination enhances immune responses and induces regression of HER2(pos) DCIS independent of route: results of randomized selection design trial, Clin Cancer Res, 23, 10.1158/1078-0432.CCR-16-1924 · DOI
  51. Lee, 2023, Dendritic cell vaccines: A shift from conventional approach to new generations, Cells., 12, 2147, 10.3390/cells12172147 · DOI
  52. Abudoureyimu, 2019, Recent progress in the emerging role of exosome in hepatocellular carcinoma, Cell Prolif., 52, 10.1111/cpr.12541 · DOI
  53. Zhou, 2017, The biology, function and clinical implications of exosomes in lung cancer, Cancer Lett, 407, 84, 10.1016/j.canlet.2017.08.003 · DOI
  54. Skotland, 2017, Lipids in exosomes: Current knowledge and the way forward, Prog Lipid Res, 66, 30, 10.1016/j.plipres.2017.03.001 · DOI · Paper page
  55. Lou, 2015, Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma, J Hematol Oncol, 8, 122, 10.1186/s13045-015-0220-7 · DOI · Paper page
  56. Toda, 2015, Effective internalization of U251-MG-secreted exosomes into cancer cells and characterization of their lipid components, Biochem Biophys Res Commun, 456, 10.1016/j.bbrc.2014.12.015 · DOI
  57. Kibria, 2018, Exosomes as a drug delivery system in cancer therapy: potential and challenges, Mol Pharm, 15, 10.1021/acs.molpharmaceut.8b00277 · DOI
  58. Salem, 2010, Mesenchymal stromal cells: current understanding and clinical status, Stem Cells, 28, 10.1002/stem.269 · DOI
  59. Schlintl, 2023, Reduced olfactory memory performance is associated with executive function deficits in older adults, Exp Aging Res, 49, 10.1080/0361073X.2022.2122651 · DOI
  60. Wang, 2020, Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer, Mol Oncol, 14, 10.1002/1878-0261.12629 · DOI
  61. Ji, 2015, Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer, Cell Cycle, 14, 10.1080/15384101.2015.1005530 · DOI
  62. Bliss, 2016, Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow, Cancer Res, 76, 10.1158/0008-5472.CAN-16-1092 · DOI
  63. Viola, 2016, Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance, Br J Haematol, 172, 10.1111/bjh.13551 · DOI
  64. Biswas, 2019, Exosomes produced by mesenchymal stem cells drive differentiation of myeloid cells into immunosuppressive M2-polarized macrophages in breast cancer, J Immunol, 203, 10.4049/jimmunol.1900692 · DOI
  65. Wan, 2020, Exosomes overexpressing miR-34c inhibit Malignant behavior and reverse the radioresistance of nasopharyngeal carcinoma, J Transl Med, 18, 12, 10.1186/s12967-019-02203-z · DOI
  66. Collingridge, 2014, Affordable cancer care: pipedream or achievable reality, Lancet Oncol, 15, 10.1016/S1470-2045(14)70062-2 · DOI
  67. Bhargava, 2012, Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation, Immunotherapy., 4, 10.2217/imt.12.40 · DOI
  68. Butterfield, 2013, Dendritic cells in cancer immunotherapy clinical trials: are we making progress, Front Immunol, 4, 10.3389/fimmu.2013.00454 · DOI
  69. Silva, 2016, Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses, Oncotarget., 7, 10.18632/oncotarget.9419 · DOI
  70. de Abreu, 2020, Native and bioengineered extracellular vesicles for cardiovascular therapeutics, Nat Rev Cardiol, 17, 10.1038/s41569-020-0389-5 · DOI

Cited by

Sorted by citations

See all 40

Metadata

Authors
Xie, J., Zheng, Z., Tuo, L., Deng, X., Tang, H., Peng, C., & Zou, Y.
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2023-11-07
Volume
14
ISSN
1664-3224
DOI
10.3389/fimmu.2023.1296857
PMC
PMC10662326
Cited by
40
References
4
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent advances in exosome-based immunotherapy applied to cancer. https://app.cochat.ai/papers/10.3389/fimmu.2023.1296857
The paper
Xie, J., Zheng, Z., Tuo, L., Deng, X., Tang, H., Peng, C., & Zou, Y. (2023). Recent advances in exosome-based immunotherapy applied to cancer. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1296857